|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
US10233251B2
(en)
*
|
2015-02-22 |
2019-03-19 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD137
|
|
EP3988577A1
(en)
*
|
2015-05-21 |
2022-04-27 |
Alligator Bioscience AB |
Anti-cd137 antibodies
|
|
US11214618B2
(en)
|
2016-06-20 |
2022-01-04 |
F-Star Therapeutics Limited |
LAG-3 binding members
|
|
NZ789594A
(en)
|
2016-06-20 |
2025-07-25 |
Kymab Ltd |
Anti-PD-L1 antibodies
|
|
CA3030636A1
(en)
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
US10899842B2
(en)
|
2016-11-23 |
2021-01-26 |
Immunoah Therapeutics, Inc. |
4-1BB binding proteins and uses thereof
|
|
EP4032911A1
(en)
*
|
2017-01-06 |
2022-07-27 |
Eutilex Co., Ltd. |
Anti-human 4-1bb antibodies and use thereof
|
|
JP6827113B2
(ja)
|
2017-01-21 |
2021-02-10 |
広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． |
シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
|
|
KR102585848B1
(ko)
|
2017-02-24 |
2023-10-11 |
마크로제닉스, 인크. |
Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
|
|
WO2018191502A2
(en)
*
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
|
MY202336A
(en)
|
2017-07-11 |
2024-04-24 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
CN111182919B
(zh)
|
2017-08-01 |
2023-07-07 |
伊莱利利公司 |
抗cd137抗体
|
|
MX2020001198A
(es)
*
|
2017-08-04 |
2020-09-07 |
Genmab As |
Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
|
|
CN111511762B
(zh)
*
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
AU2018348429B2
(en)
*
|
2017-10-10 |
2025-08-28 |
Numab Therapeutics AG |
Multispecific antibody
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
*
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
４﹘１ｂｂ抗體及其製備方法和應用
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104716A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
US11548948B2
(en)
|
2017-12-19 |
2023-01-10 |
F-Star Therapeutics Limited |
FC binding fragments comprising a PD-L1 antigen-binding site
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
MX2020008791A
(es)
*
|
2018-02-23 |
2021-01-08 |
Bicycletx Ltd |
Ligandos de peptidos biciclicos multimericos.
|
|
MX2020009863A
(es)
|
2018-03-23 |
2021-01-08 |
Lilly Co Eli |
Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
|
|
MY202157A
(en)
*
|
2018-04-09 |
2024-04-09 |
Oricell Therapeutics Co Ltd |
Anti-pd-l1 antibody and use thereof
|
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2020006374A2
(en)
*
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
EP3820898B1
(en)
|
2018-07-12 |
2025-09-03 |
invoX Pharma Limited |
Antibody molecules that bind cd137 and ox40
|
|
GB201811404D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
SG11202100170RA
(en)
|
2018-07-12 |
2021-02-25 |
F Star Beta Ltd |
Antibody molecules that bind pd-l1 and cd137
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
US11939381B2
(en)
|
2018-07-19 |
2024-03-26 |
Eli Lilly And Company |
Bispecific antibodies targeting immune checkpoints
|
|
WO2020023556A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
|
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
AU2019340530A1
(en)
*
|
2018-09-12 |
2021-03-11 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-TNFRSF9 antibodies and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
BR112021010402A2
(pt)
*
|
2018-11-30 |
2021-08-24 |
Abl Bio Inc. |
Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
|
|
CA3125451A1
(en)
*
|
2019-01-02 |
2020-07-09 |
Qlsf Biotherapeutics Inc. |
Cd137 agonist antibodies and uses thereof
|
|
EP3911682A4
(en)
*
|
2019-01-14 |
2023-03-15 |
The Regents of the University of California |
COMPOSITIONS AND METHODS TO MODULATE CELLULAR INTERNALIZATION
|
|
AU2020228367A1
(en)
*
|
2019-02-26 |
2021-10-14 |
Vivasor, Inc. |
Antigen binding proteins that bind BCMA
|
|
MX2021012961A
(es)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
|
|
JP7302028B2
(ja)
*
|
2019-06-04 |
2023-07-03 |
アカデミア シニカ |
上皮成長因子受容体を標的とするリガンド、及び腫瘍を治療するための組成物
|
|
EP3990495A4
(en)
|
2019-06-26 |
2023-11-08 |
AP Biosciences, Inc. |
ANTIBODIES FOR ACTIVATION OF T CELLS
|
|
EP4041772A4
(en)
|
2019-10-11 |
2024-04-24 |
Nanjing Leads Biolabs Co., Ltd. |
4-1BB-BINDING ANTIBODIES AND USES THEREOF
|
|
EP4100439A4
(en)
*
|
2020-02-05 |
2024-05-29 |
The Board Of Regents Of The University Of Texas System |
NOVEL LILRB2 ANTIBODIES AND USES THEREOF
|
|
EP4137155A4
(en)
*
|
2020-04-17 |
2024-10-30 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd. |
PREPARATION SPECIFICALLY RELATED TO CD137 AND ITS USE
|
|
TW202214303A
(zh)
|
2020-05-19 |
2022-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之結合分子
|
|
CN113842456B
(zh)
*
|
2020-06-28 |
2022-07-26 |
上海齐鲁制药研究中心有限公司 |
一种抗人4-1bb的单克隆抗体制剂及其用途
|
|
TW202220677A
(zh)
*
|
2020-07-31 |
2022-06-01 |
日商中外製藥股份有限公司 |
含有表現嵌合受體之細胞的醫藥組成物
|
|
CN116199778B
(zh)
*
|
2021-12-01 |
2025-06-03 |
上海君实生物医药科技股份有限公司 |
抗4-1bb抗体及其用途
|
|
CN115975032B
(zh)
*
|
2022-12-19 |
2024-06-07 |
华润生物医药有限公司 |
一种cldn18.2抗体及其应用
|
|
WO2025049858A1
(en)
*
|
2023-09-01 |
2025-03-06 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025189194A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against vegf and methods of use thereof
|